Keywords
Efeitos adversos
Uso prolongado
How to Cite
Abstract
Proton pump inhibitors (PPIs) are widely used medications to treat gastric problems, aid in the eradication of Helicobacter pylori, and prevent bleeding in patients taking nonsteroidal anti-inflammatory drugs. Despite their effectiveness, prolonged use of these medications raises concerns due to potential adverse effects. This study reviewed the literature on the risks, benefits, and indications for long-term use of PPIs. The main adverse effects identified include: increased risk of osteoporotic fractures due to malabsorption of calcium and vitamin D, hypomagnesemia, among others. However, despite these risks, PPIs are essential in certain clinical conditions. Therefore, prolonged use should be undertaken with caution, prioritizing judicious prescribing. Although adverse effects are generally rare and mild, their relevance increases with duration of use and the presence of other diseases, highlighting the importance of evidence-based practices to ensure treatment safety and efficacy.
References
Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3.
Scarpignato C, Gatta L, Zullo A, Blandizzi C. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine. 2016;14(1):179.
Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–6.
Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.
Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008;69(2):338–41.
Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–42.
Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896–904.
Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(3):225–33.
Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Laysa Moreira Peterle, Rubya Pinto Caprini, Arthur Bartoli Lopes, Izabella Trarbach Frank, Juliana Rosalém Caliman, Letícia de Barros Maroni Machado, Julia Moreno Castro de Oliveira, Cindy Sicylia Damm Sepulvida , Isabella Oliveira Bezerra, Ana Luiza Martins Porfirio, Carolina Neiva Teixeira Gama
